Jiangxi Fushine Pharmaceutical Co., Ltd.

Jiangxi Fushine Pharmaceutical Co., Ltd. is a manufacturing company listed on the ChiNext board of the Shenzhen Stock Exchange since 2015. The company specializes in the research and development, production, and sales of antibiotic active pharmaceutical ingredients (APIs) and intermediates. Fushine also focuses on expanding its technological applications in chemical synthesis and biosynthesis, while actively developing electrolyte additives for lithium batteries and mycoprotein products in the synthetic biology sector. Fushine's main business lines include the production of β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates. The company is recognized as a leading supplier of sulbactam and tazobactam globally, with a comprehensive industry chain for carbapenem products. In the lithium-ion battery sector, Fushine produces key electrolyte additives, including Vinylene carbonate and Fluoroethylene carbonate. Additionally, the company is pioneering the industrialization of filamentous fungal proteins, with a focus on sustainable and high-quality mycoprotein products that cater to various applications, including artificial meat and health care products.

1、Multi-track market share leader Fushine has been deeply cultivating in the fields of pharmaceutical intermediates and APIs for many years, with a solid position in the industry. Fushine is the world's largest supplier of sulbactam and the only supplier in the domestic sulbactam field that has passed the certification of the international regulated market. Fushine is the main supplier of tazobactam globally, and one of the most complete industry chain suppliers of penem products in the domestic; in the field of lithium battery electrolyte additives, the market share of Fushine's VC products ranks the forefront of the industry; in the field of mycoprotein, Fushine is the first domestic enterprise to achieve the tonnage industrialization of filamentous fungal proteins, with the production capacity at the forefront of the industry, and at the same time, it has developed a new type of production strains with completely independent intellectual property rights - Fusarium brachygibbosum, which has obtained the national invention patent. Fushine has been the domestic microbial filamentous fungal protein track forerunner and leader. 2、High-quality Customers and stable relationship For the pharmaceutical manufacturing business, Fushine attaches great importance to the construction of quality system, the product specifications are in line with CFDA, FDA, EDQM, PMDA and other national standards, with years of high product quality, strict quality control system, Fushine has harvested a number of stable and high-quality customers. Preparation manufacturers are strict and careful in selecting suppliers and do not change them easily once they have been identified. In foreign markets, there currently has internationally renowned pharmaceutical companies including Fresenius Kabi and Aurobindo Pharma limited; on the domestic market, there currently has Zhuhai The United Laboratories , Qilu Pharmaceuticals and Hainan General Sanyang who has a greater influence in China's antibacterial drug market, product sales are stable; For lithium battery electrolyte additives business, there has been a stable supply of Tinci materials, Capchem Technology and other well-known domestic enterprises. 3、Complete Industrial Chain In the pharmaceutical field, Fushine continues to establish and improve the product industry chain, and Fushine's penem series of products achieve the whole industry chain layout from the starting material to the downstream API; for Tazobactam series products, the Fushine has extended the layout of upstream key raw material Triazole and downstream sterile API Tazobactam sodium, and developed into a professional manufacturer and major supplier of β-lactamase inhibitors products such as Sulbactam and Tazobactam, as well as an important supplier of Carbapenems. In the field of new energy, on the one hand, the company continues to expand the variety of electrolyte additives, and currently has VC, FEC and other products in normal production and sales; on the other hand, the company intends to expand lithium bis(fluorosulphonyl)imide (LiFSI), ethylene sulphate (DTD), lithium bis(oxalate) borate (LiBOB), and other categories, to create a one-stop electrolyte materials supply platform. 4、Outstanding industrialization capability Fushine has accumulated more than twenty years of process technology and rich industry experience in the field of pharmaceutical manufacturing. In the field of new energy, downstream customers have higher requirements on the quality of additive products, as trace impurity components of electrolyte additive products may have a significant impact on the performance of lithium batteries. Through the precise control of important process links and the design and testing of production equipment, Fushine successfully entered the field of electrolyte additives in January 2022, and quickly released production capacity, by the end of 2022 has an annual output of 5,000t of VC production capacity, April 2023 growth to 8,000t per year, production capacity ranked the pioneer of the industry. On the other hand, Fushine's industrial layout is forward-looking. Chemical industry land approval, civil construction, environmental assessment and other processes will take a long time, Fushine has sufficient reserves of land, plant and environmental protection facilities, currently has eight production bases, with a land area of more than 2,000 acres, in the face of potential industry opportunities or breakthroughs in key technologies can be quickly released capacity. 5、Significant advantages in quality control and registration Fushine attaches great importance to the quality of its products, and its main products are sold in regulated markets. The regulated market has more stringent quality management requirements for manufacturers, and at the same time, its selling price is much higher than that of the non-regulated market. As sales of API and intermediate manufacturers in regulated markets need to meet local registration requirements as well as strict on-site inspections by GMP, high demands are placed on suppliers' quality management systems. The specifications of the company's main API products are formulated with reference to the United States Pharmacopoeia (USP), the European Union Pharmacopoeia (Ph.Eur.), Japan (PMDA) and other foreign pharmacopoeia standards, and are not lower than the national pharmacopoeia standards and registration standards for similar drugs. Tazobactam, Sultamicillin tosilate and Piperacillin have obtained domestic approval documents and passed the new GMP certification inspection. Tazobactam, Sulbactam and Piperacillin passed the FDA certification site inspection with the conclusion of 'zero defect'. The company's sulbactam and sulbactam sodium have passed the GMP compliance investigation of Japanese PMDA (i.e., Japanese PMDA certification); Tazobactam products passed the Korean MFDS on-site inspection; Piperacillin products obtained the European CEP certificate. The drug products adopting Fushine's Tazobactam API have been approved for sale in Europe, the United States, Canada, Australia, Korea and other markets.